To Identify An Enzyme Or Isoenzyme Patents (Class 435/7.4)
  • INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF ASPARTYL-TRNA SYNTHETASES
    Publication number: 20130280230
    Abstract: Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.
    Type: Application
    Filed: July 11, 2011
    Publication date: October 24, 2013
    Applicants: Pangu BioPharma Limited, a Tyr Pharma, Inc.
    Inventors: Leslie Ann Greene, Kyle P. Chiang, Fei Hong, Alain Philippe Vasserot, Wing-Sze Lo, Jeffry D. Watkins, Cheryl L. Quinn, John D. Mendlein
  • BROAD SPECTRUM ANTIBIOTIC ARYLOMYCIN ANALOGS
    Publication number: 20130281360
    Abstract: Arylomycin analogs are provided, wherein the analogs can have broad spectrum bioactivity. Resistance to the antibiotic bioactivity of natural product arylomycin in a range of pathogenic bacterial species has been found to depend upon single amino acid mutations at defined positions of bacterial Signal Peptidases (SPases), wherein the presence of a proline residue confers arylomycin resistance. Arylomycin analogs are provided herein that can overcome that resistance and provide for a broader spectrum of antibiotic bioactivity than can natural product arylomycins such as arylomycin A2. Methods for determining if a bacterial strain is susceptible to narrow spectrum arylomycin antibiotics, or if a broad spectrum analog is required for treatment, is provided. Pharmaceutical compositions and methods of treatment of bacterial infections, and methods of synthesis of arylomycin analogs, are provided.
    Type: Application
    Filed: August 31, 2011
    Publication date: October 24, 2013
    Applicant: The Scipps Research Institute
    Inventors: Floyd E. Romesberg, Peter A. Smith, Tucker C. Roberts
  • Total and Phosphorylated IL-1 Receptor-Associated Kinase-1 and IL-1 Receptor-Associated Kinase-4 as a Biomarker for Cancer Progression and Chemotherapy Resistance
    Publication number: 20130280264
    Abstract: Toll-like receptors (TLR) are expressed by a variety of cancers, including melanoma and T-ALL. TLR signaling plays an important role in T cell malignancies and melanoma. The effects of stimulating or inhibiting the TLR/IL-1 receptor-associated kinases IRAK-1 and IRAK-4 in melanoma and T-ALL cells were evaluated. Pharmacological treatment with an IRAK-1,-4 inhibitor delays tumor growth and prolongs survival in vitro and in vivo, indicating that TLR signaling contributes to T-ALL and melanoma progression and interfering with this signaling is a novel therapeutic strategy to control T-ALL and melanoma proliferation.
    Type: Application
    Filed: March 14, 2013
    Publication date: October 24, 2013
    Inventor: Eduardo Davila
  • PROGNOSTIC AND/OR PREDICTIVE BIOMARKERS AND BIOLOGICAL APPLICATIONS THEREOF
    Publication number: 20130281313
    Abstract: The present invention relates to the fields of genetics, immunology and medicine. The present invention more specifically relates to the identification of human genes and expression products thereof which can be used to assess the prognosis of a cancer in a subject, to assess the sensitivity of a subject to a treatment of cancer, or monitor, in particular determine the efficacy, of such a treatment of cancer after a given period of time. Said human genes and expression products can further be used (i) in the prevention or treatment of cancer, in particular to determine or select the appropriate cancer treatment for a given subject and/or for a particular tumor, as well as (ii) for the screening of therapeutically active drugs.
    Type: Application
    Filed: September 1, 2011
    Publication date: October 24, 2013
    Applicant: INSTITUT GUSTAVE ROUSSY
    Inventors: Lorenzo Galluzzi, Annick Harel-Bellan, Guido Kroemer, Ken Olaussen, Jean-Charles Soria
  • METHOD TO DETERMINE EMBRYO AND OOCYTE QUALITY BASED ON CERAMIDASE
    Publication number: 20130280717
    Abstract: The present invention relates to a method of predicting the likelihood of embryo or oocyte survival. This method involves providing a sample of an embryo, an oocyte, or surrounding liquid or cells, and screening the sample for ceramidase expression or activity. The ceramidase expression or activity obtained through said screening is then correlated to a prediction of the likelihood of embryo or oocyte survival. Also disclosed is a kit.
    Type: Application
    Filed: June 20, 2013
    Publication date: October 24, 2013
    Inventors: Edward H. Schuchman, Efrat Eliyahu
  • ENGINEERED CONFORMATIONALLY-STABILIZED PROTEINS
    Publication number: 20130281314
    Abstract: Provided herein are conformationally stabilized ubiquitin proteins and methods for using the same to identify agents that bind to the stabilized ubiquitin protein or that bind to a protein that interacts with or processes the stabilized form of the ubiquitin protein. Also provided herein are methods for screening for conformationally stabilized proteins having increased binding affinity to a binding partner in comparison to the binding affinity of the wildtype form of the protein to the binding partner.
    Type: Application
    Filed: March 14, 2013
    Publication date: October 24, 2013
    Inventors: Jacob E. CORN, Yingnan ZHANG, Aaron H. PHILLIPS
  • DDX3 AS A BIOMARKER FOR CANCER AND METHODS RELATED THERETO
    Publication number: 20130281440
    Abstract: The invention encompasses methods for treating or preventing diseases and disorders associated abnormal cell growth, for example, treating or preventing cancer or tumor growth, by administering to a subject in need thereof a composition comprising a therapeutically or prophylactically effective amount of a compound that downregulates DDX3, for example a fused diimidazodiazepine ring compound or a pharmaceutically acceptable salt thereof. The invention also encompasses the use of DDX3 as a biomarker for diagnostic and treatment purposes, for example, to identify a hyperproliferative disorder susceptible to treatment by down regulation of DDX3.
    Type: Application
    Filed: March 15, 2013
    Publication date: October 24, 2013
    Inventor: The Johns Hopkins University
  • Diagnostic marker for type 1 diabetes mellitus
    Patent number: 8563327
    Abstract: The present invention provides, as a novel diagnosis marker for type 1 diabetes mellitus, a type 1 diabetes mellitus diagnostic composition comprising alanyl-tRNA synthetase, glycyl-tRNA synthetase, asparaginyl-tRNA synthetase, or tryptophanyl-tRNA synthetase, a diagnostic kit comprising the same, and a diagnostic method using the same. The composition, the kit, and the method, according to the present invention, may be used for early diagnosis and confirmed diagnosis of type 1 diabetes mellitus because type 1 diabetes mellitus can be easily diagnosed from a patient sample.
    Type: Grant
    Filed: August 5, 2011
    Date of Patent: October 22, 2013
    Assignees: Seoul National University Hospital, SNU R&DB Foundation
    Inventors: Sang Gyu Park, Kyong Soo Park, Sunghoon Kim
  • Therapeutic Antibodies against ROR-1 Protein and Methods for Use of Same
    Publication number: 20130273073
    Abstract: Therapeutic antibodies having binding specificity for ROR-1 expressed on cancer cells (particularly leukemic and lymphomic cells) and pharmaceutical compositions containing one or more such antibodies for use in treating cancer. Methods for diagnosing such cancers through in vitro detection of binding to ROR-1 protein expressed on putative cancer cells are also provided.
    Type: Application
    Filed: January 13, 2012
    Publication date: October 17, 2013
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Thomas J. Kipps, George F. Widhopf, II, Bing Cui
  • 1L1RL-1 as a Cardiovascular Disease Marker and Therapeutic Target
    Publication number: 20130273562
    Abstract: This invention pertains to methods and compositions for the diagnosis and treatment of cardiovascular conditions. More specifically, the invention relates to isolated molecules that can be used to diagnose and/or treat cardiovascular conditions including cardiac hypertrophy, myocardial infarction, stroke, arteriosclerosis, and heart failure.
    Type: Application
    Filed: March 7, 2013
    Publication date: October 17, 2013
    Inventor: Richard T. Lee
  • DETECTION, ISOLATION AND USES OF RENALASE (MONOAMINE OXIDASE C)
    Publication number: 20130273023
    Abstract: The present invention provides for the identification, isolation and uses of mammalian Monoamine Oxidase C (MAO-C), also known as renalase.
    Type: Application
    Filed: April 21, 2011
    Publication date: October 17, 2013
    Applicant: YALE UNIVERSITY
    Inventors: JIANCHAO XU, GARY DESIR
  • NMR SYSTEMS AND METHODS FOR THE RAPID DETECTION OF ANALYTES
    Publication number: 20130273522
    Abstract: This invention features systems and methods for the detection of analytes, and their use in the treatment and diagnosis of disease.
    Type: Application
    Filed: March 28, 2013
    Publication date: October 17, 2013
    Inventors: THOMAS JAY LOWERY, JR., MARK JOHN AUDEH, JAMES FRANKLIN CHEPIN, Vasiliki Demas, Rahul K. Dhanda, MARILYN LEE FRITZEMEIER, MATTHEW BLANCO, ISAAC KOH, SONIA KUMAR, BRIAN M. MOZELESKI, LORI ANNE NEELY, DANIELLA LYNN PLOURDE, CHARLES WILLIAM RITTERSHAUS
  • Abnormalities of Phosphatase 2A (PP2A) for Diagnosis and Treatment of Alzheimer's Disease
    Publication number: 20130273545
    Abstract: This invention relates to methods of diagnosing Alzheimer's disease and methods of screening for compounds for the treatment or prevention of Alzheimer's disease. The methods are based upon newly discovered differences in protein phosphatase 2A (PP2A) function and related molecular events in Alzheimer's disease cells compared to control cells. In one embodiment, differences in basal PP2A gene expression in Alzheimer's cells are compared to controls. In another embodiment differences in PP2A protein and enzyme activity are compared in test and control cells. In another embodiment differences in response to substances that inhibit PP2A function are compared. Still another embodiment detects differences in the subcellular distribution of phosphorylated Erk1/2, a substrate of PP2A, in normal and Alzheimer's disease cells.
    Type: Application
    Filed: February 15, 2013
    Publication date: October 17, 2013
    Inventors: Wei-Qin Zhao, Daniel L. Alkon
  • DEVICE FOR PERFORMING AN ENZYME-BASED DIAGNOSTIC TEST AND METHODS FOR USE THEREOF
    Publication number: 20130273563
    Abstract: Enzyme-based diagnostic testing systems for detecting and quantifying at least one of the activity level or the concentration of an enzyme or a biochemical analyte in a biological sample. Such enzyme-based diagnostic testing systems can provide rapid, accurate, affordable laboratory-quality testing at the point of care. An enzyme-based diagnostic testing system may include a lateral-flow chromatographic assay cassette that is configured for assaying an amount or activity of an enzyme in a sample or for enzymatically determining the concentration of an enzyme substrate in a sample. Additionally, the enzyme-based diagnostic testing systems may include testing devices (e.g., a smartphone or a similar remote computing device) having data collection and data analysis capabilities. Such testing devices may also include automated data reporting and decision support.
    Type: Application
    Filed: April 12, 2013
    Publication date: October 17, 2013
    Inventor: Joel R. L. Ehrenkranz
  • GENE EXPRESSION IN N-CADHERIN OVEREXPRESSING PROSTATE CANCERS AND THEIR CONTROLS
    Publication number: 20130274128
    Abstract: The present invention provides methods of diagnosing a cancer or providing a prognosis for a cancer by analyzing the level of expression of a marker that is a downstream target of N-cadherin.
    Type: Application
    Filed: September 20, 2011
    Publication date: October 17, 2013
    Applicant: The Regents of the University of Califorina
    Inventor: Robert E. Reiter
  • METHOD FOR INDUCING CELL SENESCENCE BY RECOMBINANT INTERFERON WITH ALTERED SPATIAL CONFIGURATION
    Publication number: 20130273527
    Abstract: This invention provides a method for inducing cell senescence by recombinant interferon with altered spatial configuration, wherein the interferon is encoded by a nucleotide sequence having the sequence of SEQ ID NO.2.
    Type: Application
    Filed: April 12, 2013
    Publication date: October 17, 2013
    Applicant: SUPERLAB FAR EAST LIMITED
    Inventors: Guangwen Wei, Huiling Li, Dongqin Yang, Xin Cao, Hongling Huang, Miao Ding, Haineng Xu, Xinyuan Liu, Mingyang Li
  • Methods and Compositions for Inducing Deregulation of EPHA7 and ERK Phosphorylation in Human Acute Leukemias
    Publication number: 20130267579
    Abstract: Methods for assessing a pathological condition in a subject include measuring one or more markers where a difference is indicative of acute lymphoblastic leukemia (ALL) or a predisposition to ALL, uses and compositions are disclosed.
    Type: Application
    Filed: June 13, 2013
    Publication date: October 10, 2013
    Inventor: Carlo M. Croce
  • METHODS FOR BLOCKING CELL PROLIFERATION AND TREATING DISEASES AND CONDITIONS RESPONSIVE TO CELL GROWTH INHIBITION
    Publication number: 20130266636
    Abstract: In alternative embodiments, the invention provides methods for regulating or modulating RAF kinases. In alternative embodiments, the invention provides methods for ameliorating, preventing and/or treating diseases, infections and/or conditions having unwanted, pathological or aberrant cell proliferation, or that are responsive to inhibition or arrest of cell growth, by administration of an allosteric RAF inhibitor and/or any agent which prevents localization of RAF to mitotic spindles or mid-bodies.
    Type: Application
    Filed: August 12, 2011
    Publication date: October 10, 2013
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: David Cheresh, Eric Murphy, Ainhoa Mielgo
  • DIAGNOSIS AND RISK STRATIFICATION BY MEANS OF THE NOVEL MARKER CT-PROADM
    Publication number: 20130266961
    Abstract: The invention relates to a novel diagnostic marker CT-proADM (C-terminal fragment of preproADM, SEQ ID No. 1) for diagnosing and/or stratifying the risk of diseases. Also disclosed is a method for diagnosing and/or stratifying the risk of diseases, particularly cardiovascular diseases, cardiac insufficiency, and infections and/or inflammations of the lungs and respiratory tract. In said method, the CT-proADM (SEQ ID No. 1) marker, or a partial peptide of fragment thereof, or said marker contained in a marker combination (panel, cluster) is determined in a patient who is to be examined. The invention further relates to a diagnostic apparatus as well as a kit for carrying out said method.
    Type: Application
    Filed: March 1, 2013
    Publication date: October 10, 2013
    Inventors: Andreas Bergmann, Joachim Struck
  • MEANS AND METHODS FOR DIAGNOSING CANCER USING AN ANTIBODY WHICH SPECIFICALLY BINDS TO BRAF V600E
    Publication number: 20130266962
    Abstract: The present invention relates to the field of diagnostic tests and diagnostic tools. Specifically, contemplated is to a method for diagnosing cancer in a sample of a subject suspected to suffer from cancer comprising contacting the sample with an antibody which specifically binds to the epitope characterized by SEQ ID NO 1 on a BRAF polypeptide under conditions which allow for binding of said antibody to the epitope and determining binding of the antibody to the epitope, whereby cancer is diagnosed. Further contemplated are antibodies which specifically bind to the epitope characterized by SEQ ID NO 1 on a BRAF polypeptide and a device or kit comprising such antibodies.
    Type: Application
    Filed: September 30, 2011
    Publication date: October 10, 2013
    Applicants: RUPRECHT-KARLS-UNIVERSITÄT HEIDELBERG, DEUTSCHES KREBSFORSCHUNGSZENTRUM
    Inventor: Ulrike Zentgraf
  • Bioluminescent detection of cyanohydroxy benzothiazole compounds
    Patent number: 8551721
    Abstract: The invention provides methods that employ derivatives of 2-cyano-6-hydroxy- or 2-cyano-6-amino-benzothiazole, for example, in a bioluminogenic reaction. Also provided are novel compounds that can be used in the methods. The invention further provides methods for detecting or determining the presence of molecules and/or enzymes, the modulator activity of such molecules, and/or the activity of such enzymes. The methods are adaptable to high-throughput format.
    Type: Grant
    Filed: September 9, 2009
    Date of Patent: October 8, 2013
    Assignee: Promega Corporation
    Inventors: Jessica Anderson, Poncho Meisenheimer, John Shultz, James J. Cali, Dongping Ma
  • Selection and enrichment of proteins using in vitro compartmentalization
    Patent number: 8551734
    Abstract: Compositions and methods are provided for selection and enrichment of a target gene from a library of polynucleotide sequences such as might be formed from a genome or by random mutagenesis of a genetic sequence. The selection and enrichment occurs in aqueous droplets formed in an emulsion that compartmentalize individual polynucleotides from the library or a plurality of polynucleotides that may include polynucleotides not derived from the library, transcription and translation reagents and optionally additional chemical and enzyme reagents. The selection and enrichment method utilizes a polynucleotide adaptor which when ligated to the polynucleotide fragment enables amplification to occur in the presence of an adaptor specific primer.
    Type: Grant
    Filed: March 8, 2012
    Date of Patent: October 8, 2013
    Inventors: Yu Zheng, Richard J. Roberts
  • BETA-2 MICROGLOBULIN AS A BIOMARKER FOR PERIPHERAL ARTERY DISEASE
    Publication number: 20130260389
    Abstract: The present invention provides ?2 microglobulin as a biomarker for qualifying or assessing peripheral artery disease in a subject.
    Type: Application
    Filed: January 16, 2013
    Publication date: October 3, 2013
    Applicants: Board of Trustees of the Leland Stanford Junior Un University, Vermillion, Inc.
    Inventors: John P. Cooke, Eric T. Fung, Eiichiro Kimura
  • Methods and Compositions for Highly Sensitive Detection of Molecules
    Publication number: 20130260390
    Abstract: The present invention discloses methods for the detection and monitoring of a condition in a subject using highly sensitive detection of molecules. The invention provides a method for detecting or monitoring a condition in a subject, comprising detecting a first marker in a first sample from the subject and detecting a second marker, wherein the first marker comprises a biomarker, e.g., Cardiac Troponin-I (cTnI) or Vascular Endothelial Growth Factor (VEGF), and wherein the limit of detection of the first marker is less than about 10 pg/ml. The second marker can be a biomarker, physiological marker, a molecular marker or a genetic marker.
    Type: Application
    Filed: March 12, 2013
    Publication date: October 3, 2013
    Inventors: Philippe J. Goix, Robert Puskas, John Todd, Richard Livingston, Douglas Held, Sarah Le
  • Method Of Determining The Protease Cathepsin B In A Biological Sample
    Publication number: 20130260391
    Abstract: A method for determination of the potentially available activity of cathepsin B in a biological sample, including the activity of the active form of cathepsin B, the form of cathepsin B which can be activated from the pro-form procathepsin B being present in the sample, and the form of cathepsin B which can be activated and which is inhibited in the sample in its activity by protease inhibitor, whereby the procathepsin B being present in the sample is converted into the active form of cathepsin B, the free protease inhibitor for cathepsin B being present in the sample is depleted from the sample or its inhibitor function is suppressed, and the protease inhibitor is withdrawn from the inhibited form of cathepsin B, and subsequently the activity of the active cathepsin B in the sample is determined.
    Type: Application
    Filed: July 1, 2011
    Publication date: October 3, 2013
    Inventors: Hans Jörg Meier, Hanns Jörg Mauk
  • NMR SYSTEMS AND METHODS FOR THE RAPID DETECTION OF ANALYTES
    Publication number: 20130260367
    Abstract: This invention features systems and methods for the detection of analytes, and their use in the treatment and diagnosis of disease.
    Type: Application
    Filed: October 19, 2011
    Publication date: October 3, 2013
    Applicant: T2 Biosystems, Inc.
    Inventors: Thomas Jay Lowery, JR., Mark John Audeh, Matthew Blanco, James Franklin Chepin, Vasiliki Demas, Rahul Dhanda, Marilyn Lee Fritzemeier, Isaac Koh, Sonia Kumar, Lori Anne Neely, Brian Mozeleski, Daniella Lynn Plourde, Charles William Rittershaus, Parris Wellman
  • ANCCA as a Diagnostic Biomarker and Therapeutic Target for Breast Cancers
    Publication number: 20130261167
    Abstract: The present invention provides methods of diagnosing breast cancer, confirming a diagnosis of breast cancer, predicting the survival of a breast cancer patient, and providing a therapeutic target of treatment in a breast cancer patient by measuring relatively increased expression levels of ANCCA. Expression levels of ANCCA can be measured be determining the levels mRNA or protein. The expression levels can be compared to a predetermined threshold level or to a control, e.g., a positive or negative control.
    Type: Application
    Filed: September 23, 2011
    Publication date: October 3, 2013
    Applicant: The Regents Of The University Of California
    Inventors: Hong-Wu Chen, June X. Zou
  • Methods for determination of calcineurin activity and uses in predicting therapeutic outcomes
    Patent number: 8546095
    Abstract: The methods of the disclosure provide fluorescence-based assays for calcineurin activity, especially in isolated T cells. The methods include the stimulation of the T cells with agents that specifically target the TCR with or without influencing co-stimulatory pathways. One TCR agonist is monoclonal antibodies specific for CD3, which more precisely distinguish the inducible activity of calcineurin than does an alternative method targeting the T cell receptor (CD3) combined with CD28 costimulation. This method more accurately distinguishes between the measured level of calcineurin activity of T cells from immunosuppressed transplant recipients and normal individuals, and thus has improved diagnostic accuracy with respect to the response of an individual to immunosuppressant therapy following an organ transplant.
    Type: Grant
    Filed: January 20, 2010
    Date of Patent: October 1, 2013
    Assignee: Emory University
    Inventors: James Tumlin, Allan D. Kirk, Brian R. Roberts, Jennifer Gooch
  • Procalcitonin gene expression as a precise biomarker of aging process
    Publication number: 20130252254
    Abstract: The invention relates to a method for diagnosis and/or complications and/or risk assessment of aging, in particular of aging process, wherein a determination of the marker procalcitonin (PCT: SEQ ID No. 1) or a partial peptide or fragment thereof or if contained in a marker combination (Panel, Cluster) is carried out on a patient within normal value ranges of leucocytes under investigation. The invention further relates to invent new drugs, a diagnostic device and a kit for carrying out said method.
    Type: Application
    Filed: April 9, 2012
    Publication date: September 26, 2013
    Inventor: Mehmet Ali Soylemez
  • BLADDER CANCER DIAGNOSIS COMPOSITION CONTAINING APE1/REF-1 AND BLADDER CANCER DIAGNOSTIC KIT USING SAME
    Publication number: 20130252255
    Abstract: Provided are a bladder cancer diagnosis composition containing APE1/Ref-1, a bladder cancer diagnostic kit containing an antibody which specifically binds to the APE1/Ref-1, and a method of measuring APE1/Ref-1 concentration in biological samples through an antigen-antibody binding reaction using the antibody which specifically binds to the APE1/Ref-1. According to the invention, the APE1/Ref-1 protein concentration in serum of bladder cancer patients is significantly higher than in healthy subjects, and more particularly, it significantly increases in the serum of patients with stage 2 or later bladder cancer.
    Type: Application
    Filed: December 8, 2011
    Publication date: September 26, 2013
    Applicant: THE INDUSTRY & ACADEMY COOPERARATION IN CHUNGNAM NATIONAL UNIVERSITY (IAC)
    Inventors: Byeong-Hwa Jeon, Sung-A Choi, Ju-Hyun Shin
  • ACTIVATING PHOSPHORYLATION SITE ON GLUTAMINASE C
    Publication number: 20130252983
    Abstract: A method of reducing the production of glutamate from glutamine by glutaminase C in a cell or tissue. The method involves inhibiting activating phosphorylation of glutaminase C under conditions effective to reduce production of glutamate from glutamine. Methods for treating or preventing a condition mediated by the activating phosphorylation of glutaminase C, detecting a condition mediated by the activating phosphorylation of glutaminase C, and screening for compounds capable of treating or preventing cancer are also disclosed.
    Type: Application
    Filed: September 12, 2011
    Publication date: September 26, 2013
    Applicant: CORNELL UNIVERSITY
    Inventors: Kristin Wilson Cerione, Richard A. Cerione
  • Tau Acetylation in the Pathogenesis of Alzheimers Disease and Other Related Tauopathies
    Publication number: 20130251731
    Abstract: The present invention relates to biomarkers and diagnostic methods for Alzheimer's disease and other neurodegenerative disorders. The invention also provides compositions for detecting the biomarker as well as compositions and methods useful for treating Alzheimer's disease and other neurodegenerative disorders.
    Type: Application
    Filed: March 13, 2013
    Publication date: September 26, 2013
    Applicant: The Trustees of the University of Pennsylvania
    Inventors: Virginia M.Y. Lee, Todd J. Cohen, John Q. Trojanowski
  • METHOD FOR MEASURING RESISTANCE OR SENSITIVITY TO DOCETAXEL
    Publication number: 20130252837
    Abstract: The present invention relates to novel and useful methods that predict or monitor a patient's response to a molecule of the taxoid family by measuring the increase or decrease of specific genetic markers as compared to controls. The present invention also provides kits that predict of monitor patient's response to a molecule of the taxoid family by measuring nucleic acid or protein levels of particular genetic markers and comparing their levels to controls or reference markers.
    Type: Application
    Filed: March 15, 2013
    Publication date: September 26, 2013
    Applicant: Sanofi US
    Inventors: Dorre GRUENEBERG, Xi HUANG, Sridaran NATESAN, Paul AUGUST
  • Diagnostic Methods
    Publication number: 20130252834
    Abstract: The invention relates to a method of aiding the diagnosis of acute brain damage in a subject, said method comprising (i) assaying the concentration of at least one oxidative stress polypeptide selected from the group consisting of: PRDX1, PRDX6 and GSTP1 in a sample from said subject; and (ii) assaying the concentration of at least one further polypeptide selected from Panel A; (Hi) comparing the concentrations of (i) and (ii) to the concentrations of the polypeptides in a reference standard and determining quantitative ratios for said polypeptides; (iv) wherein a finding of a quantitative ratio of each of the assayed polypeptides in the sample to the polypeptides in the reference standard of greater than 1.3 indicates an increased likelihood of acute brain damage having occurred in said subject.
    Type: Application
    Filed: May 23, 2011
    Publication date: September 26, 2013
    Applicants: UNIVERSITE DE GENEVE, ELECTROPHORETICS LIMITED
    Inventors: Loic Gerard Dayon, Jean-Charles Sanchez, Joan Montaner Villalonga
  • INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF LYSYL-TRNA SYNTHETASES
    Publication number: 20130243745
    Abstract: Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.
    Type: Application
    Filed: June 1, 2011
    Publication date: September 19, 2013
    Applicants: ATYR PHARMA, INC.
    Inventors: Leslie Ann Greene, Kyle P. Chiang, Fei Hong, Alain Philippe Vasserot, Wing-Sze Lo, Jeffry Dean Watkins, Cheryl L. Quinn, John D. Mendlein
  • COMBINATION THERAPY FOR CHEMORESISTANT CANCERS
    Publication number: 20130244950
    Abstract: Methods of treating, preventing or managing triple negative breast cancer (TNBC) or clear cell renal cell carcinoma (ccRCC) are disclosed. The methods encompass the administration of an HDAC inhibitor romidepsin in combination with a cytidine analog. Pharmaceutical compositions and single unit dosage forms suitable for use in the methods provided herein are also disclosed.
    Type: Application
    Filed: September 26, 2012
    Publication date: September 19, 2013
    Applicant: Celgene Corporation
    Inventors: John A. Copland, III, Han Win Tun, Simon James Cooper, Laura Ann Marlow
  • EVALUATING MMP EXPRESSION IN PATIENT STRATIFICATION AND OTHER THERAPEUTIC, DIAGNOSTIC AND PROGNOSTIC METHODS FOR CANCER
    Publication number: 20130244890
    Abstract: Provided are compositions, methods and kits for quantifying the expression and/or activity of MMP-14 and other biomarkers of cancer, which may be used diagnostically and prognostically, e.g., in patient stratification and evaluation of appropriate therapeutic regimens.
    Type: Application
    Filed: April 24, 2012
    Publication date: September 19, 2013
    Applicant: DYAX CORP.
    Inventors: Clive R. Wood, Daniel T. Dransfield, Laetitia Devy
  • Assay for identifying a modulator of HIF hydroxylase
    Patent number: 8535899
    Abstract: A novel class of hydroxylases is described having the amino acid sequence of SEQ ID NO: 2, 4, 6 and 8, and variants and fragments thereof having HIF hydroxylation activity. The polypeptides of the invention have in particular prolyl hydroxylase activity. An assay method monitors the interaction of the HIF hydroxylase with a substrate. Modulators of HIF hydroxylase are provided for use in the treatment of a condition associated with increased or decreased HIF levels or activity or for the treatment of a condition where it is desirable to modulate HIF levels or activity.
    Type: Grant
    Filed: January 12, 2010
    Date of Patent: September 17, 2013
    Assignee: Isis Innovation Limited
    Inventors: Patrick Henry Maxwell, Christopher William Pugh, Peter John Ratcliffe, Christopher Joseph Schofield
  • METHOD FOR PREDICTING A NEED FOR RENAL REPLACEMENT THERAPY (RRT)
    Publication number: 20130236908
    Abstract: A method for predicting a need for Renal Replacement Therapy (RRT) in a patient comprises: determining a concentration of pi glutathione S transferase-(?GST) in a first urine sample from the patient; and wherein a need for RRT is predicted when the ?GST concentration is determined to be elevated in comparison to a patient without kidney injury. The method according to the invention can further comprise detecting for the presence of risk factors for RRT in a patient, the risk factors including elevated serum creatinine concentration, type I diabetes, type II diabetes, hypertension, dyslipidemia, hyperglycaemia, proteinuria and hypoalbuminemia.
    Type: Application
    Filed: April 19, 2013
    Publication date: September 12, 2013
    Applicant: ARGUTUS INTELLECTUAL PROPERTIES LIMITED
    Inventor: ARGUTUS INTELLECTUAL PROPERTIES LIMITED
  • INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF METHIONYL-TRNA SYNTHETASES
    Publication number: 20130236440
    Abstract: Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.
    Type: Application
    Filed: May 3, 2011
    Publication date: September 12, 2013
    Applicants: PANGU BIOPHARMA LIMITED, ATYR PHARMA, INC.
    Inventors: Leslie Ann Greene, Kyle P. Chiang, Fei Hong, Alain Philippe Vasserot, Jeffry D. Watkins, Cheryl L. Quinn, Wing-Sze Lo, John D. Mendlein
  • BENZOCYANINE COMPOUNDS
    Publication number: 20130230465
    Abstract: Compounds useful as labels with properties comparable to known fluorescent compounds. The compounds are conjugated to proteins and nucleic acids for biological imaging and analysis. Synthesis of the compounds, formation and use of the conjugated compounds, and specific non-limiting examples of each are provided.
    Type: Application
    Filed: February 27, 2013
    Publication date: September 5, 2013
    Inventors: Greg Hermanson, Peter T. Czerney, Surbhi Desai, Matthias S. Wenzel, Boguslawa R. Dworecki, Frank G. Lehmann, Marie Christine Nlend
  • INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF TYROSYL-tRNA SYNTHETASES
    Publication number: 20130230508
    Abstract: Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.
    Type: Application
    Filed: August 25, 2011
    Publication date: September 5, 2013
    Applicants: PANGU BIOPHARMA LIMITED, ATYR PHARMA, INC.
    Inventors: Leslie Ann Greene, Kyle P. Chiang, Fei Hong, Alain Philippe Vasserot, Wing-Sze Lo, Jeffry D. Watkins, Cheryl L. Quinn, John D. Mendlein
  • Complement Pathway Inhibitors Binding To C5 and C5A Without Preventing The Formation of C5B
    Publication number: 20130230522
    Abstract: The invention relates to inhibitors that bind to C5 and C5a, but which do not prevent the activation of C5 and do not prevent formation of or inhibit the activity of C5b. One example of such an inhibitor molecule is the monoclonal antibody designated MAb137-26, which binds to a shared epitope of human C5 and C5a. These inhibitors may be used to inhibit the activity of C5a in treating diseases and conditions mediated by excessive or uncontrolled production of C5a. The inhibitor molecules are also useful for diagnostic detection of the presence/absence or amount of C5 or C5a.
    Type: Application
    Filed: February 5, 2013
    Publication date: September 5, 2013
    Applicant: Genentech, Inc.
    Inventors: Michael Fung, Meisheng Lu, William N. C. Sun, Cecily R. Y. Sun
  • INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF P38 MULTI-TRNA SYNTHETASE COMPLEX
    Publication number: 20130230507
    Abstract: Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.
    Type: Application
    Filed: May 4, 2011
    Publication date: September 5, 2013
    Applicant: ATYR PHARMA, INC.
    Inventors: Leslie Ann Greene, Kyle P. Chiang, Alain Philippe Vasserot, Jeffry Dean Watkins, Cheryl L. Quinn, John D. Mendlein
  • INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF GLUTAMINYL-TRNA SYNTHETASES
    Publication number: 20130230505
    Abstract: Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.
    Type: Application
    Filed: May 26, 2011
    Publication date: September 5, 2013
    Applicants: Pangu BioPharma Limited, aTyr Pharma Inc.
    Inventors: Leslie Ann Greene, Kyle P. Chiang, Fei Hong, Alain Philippe Vasserot, Wing-Sze Lo, Jeffry Dean Watkins, Cheryl L. Quinn, John D. Mendlein
  • USE OF MOLECULAR MARKERS FOR THE PRECLINICAL PROFILING OF INHIBITORS OF ENZYMES HAVING HISTONE DEACETYLASE ACTIVITY
    Publication number: 20130231472
    Abstract: The present invention relates to the use of molecular markers and related signaling mechanisms for the preclinical and clinical profiling of inhibitors of enzymes having histone deacetylase activity. The invention also relates to the use of such markers as diagnostic and/or prognostic tools for the treatment of tumor patients with such inhibitors.
    Type: Application
    Filed: April 16, 2012
    Publication date: September 5, 2013
    Inventors: Thorsten HEINZEL, Oliver H. Kraemer, Martin Goettlicher, Ping Zhu, Martin Golebiewski, Pier Giuseppe Pelicci, Alexander B. Maurer, Bernd Hentsch, Saverio Minucci
  • METHODS FOR DIAGNOSIS AND TREATMENT OF PROLIFERATIVE DISORDERS MEDIATED BY CD40 SIGNALING
    Publication number: 20130230528
    Abstract: Methods for identifying subjects having a cancer or pre-malignant condition that will benefit from anti-CD40 therapeutic agents that modulate CD40L-mediated CD40 signaling are provided. The methods comprise the use of biomarkers of cellular apoptosis, cell proliferation and survival, and CD40 signaling pathways to monitor ex vivo response to one or more anti-CD40 therapeutic agents of interest that modulate CD40 signaling on CD40-expressing neoplastic cells. The ex vivo prognostic assays can be used alone or in conjunction with other prognostic assays to identify candidate subjects who will benefit from treatment with anti-CD40 therapeutic agents. Methods of the invention also comprise the use of these biomarkers to monitor in vivo efficacy of treatment with an anti-CD40 therapeutic agent.
    Type: Application
    Filed: December 17, 2012
    Publication date: September 5, 2013
    Applicants: XOMA TECHNOLOGY LTD., NOVARTIS AG
    Inventors: Sharon Lea Aukerman, Bahija Jallal, Mohammad Luqman
  • Methods for Monitoring Methotrexate Therapy
    Publication number: 20130230865
    Abstract: The present invention provides methods for assessing efficacy of a methotrexate (MTX) dosing regimen in a patient.
    Type: Application
    Filed: September 13, 2011
    Publication date: September 5, 2013
    Inventor: Thierry Dervieux
  • INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF GLYCYL-TRNA SYNTHETASES
    Publication number: 20130224174
    Abstract: Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.
    Type: Application
    Filed: July 12, 2011
    Publication date: August 29, 2013
    Applicants: PANGU BIOPHARMA LIMITED, ATYR PHARMA, INC.
    Inventors: Leslie Ann Greene, Kyle P. Chiang, Fei Hong, Alain Philippe Vasserot, Wing-Sze Lo, Jeffry Dean Watkins, Cheryl L. Quinn, John D. Mendlein
  • BIOLOGICAL MOLECULE DETECTING APPARATUS AND BIOLOGICAL MOLECULE DETECTING METHOD
    Publication number: 20130224763
    Abstract: A biological molecule detecting apparatus capable of highly sensitive measurements is provided. A laser was emitted onto a solution, to impart external force onto free molecules and binding molecules within the solution. The external force inhibited Brownian motion of the free molecules and the binding molecules. The concentration of a detection target substance which is associated the binding molecules can be measured with high sensitivity, by measuring the Brownian motion of the free molecules and the binding molecules within the solution irradiated with the laser.
    Type: Application
    Filed: April 1, 2013
    Publication date: August 29, 2013
    Applicant: FUJIFILM CORPORATION
    Inventor: FUJIFILM CORPORATION